Circulation Reports
Online ISSN : 2434-0790
Heart Failure
Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
Makiko NakamuraTeruhiko ImamuraMasakazu HoriRyuichi UshijimaShuji JohoKoichiro Kinugawa
Author information
JOURNALS OPEN ACCESS FULL-TEXT HTML

2020 Volume 2 Issue 8 Pages 420-424

Details
Abstract

Background:Transthyretin amyloid cardiomyopathy is a progressive disease with a poor prognosis. There had been no specific treatment for transthyretin amyloid cardiomyopathy until tafamidis received expanded approval in March 2019 in Japan. However, the clinical efficacy of tafamidis remains unknown.

Methods and Results:We initiated tafamidis treatment in 9 patients (median age 78 years; 89% male) from May 2019 to April 2020. Within 6 months after initiation, 1 patient discontinued prematurely and 2 patients were hospitalized due to worsening heart failure, with 1 of these patients discontinuing therapy. There were no significant changes in plasma B-type natriuretic peptide and serum troponin I concentrations over the 6-month treatment period, but interventricular septum thickness increased in 3 of 6 patients.

Conclusions:Further evaluation of tafamidis therapy in a larger patient cohort with transthyretin amyloid cardiomyopathy is warranted to determine the optimal therapeutic strategy.

Information related to the author
© 2020 THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Previous article Next article
feedback
Top